From Molecular characterization to Targeted therapy design
From molecular characterization to targeted therapy design: Future personalized immunotherapy for pediatric patients with rare tumors
Children and young adults with advanced solid tumors continue to face poor outcomes, with survival rates improving only modestly over the past several decades. One major challenge is that pediatric cancers are highly diverse. More than 150 distinct tumor subtypes have been identified, and many are extremely rare. As a result, it is often difficult to develop effective targeted therapies or conduct sufficiently powered clinical trials for individual tumor types. At the same time, combining many biologically different cancers into a single trial may overlook important differences between patients and can increase the risk of ineffective treatment or long-term side effects.
Our long-term goal is to help advance precision medicine for children with rare and understudied cancers. Emerging technologies—including next-generation sequencing, single-cell genomics, and spatial transcriptomics—now allow us to examine the molecular features of a patient's tumor in unprecedented detail, even from small biopsy samples obtained at diagnosis. By integrating these data with computational and artificial intelligence–based approaches, we hope to better understand the biological drivers of each patient's disease and identify therapies that are most likely to be effective.
Researchers can contribute at many stages of this process, from molecular characterization of tumors at diagnosis or relapse, to the development of new targeted and immune-based therapies, the repurposing of existing treatments, and ultimately the design of more personalized treatment strategies. Through these efforts, we hope to help move cancer care toward a future in which therapies are tailored to the unique biology of each patient's tumor.
